- The product developed by Pfizer and BioNTech is 90% effective, the producer says. The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
- Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
- After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the Data Monitoring Committee performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose.
- Pfizer says there are no serious side effects. If key indicators are safe, the world may have a tool to tackle the pandemic in a week.
- The European Commission has already agreed to sign an agreement with the developers on the purchase of 300 million doses of the coronavirus vaccine.
Zelensky asks Merkel to assist in allocating COVID-19 vaccine to Ukraine

The parties agreed to further coordinate efforts to overcome the consequences of the pandemic.
President of Ukraine Volodymyr Zelensky on November 10 had a phone call with Germany's Chancellor Angela Merkel during which he asked the German leader to assist in supplying a U.S.-German-developed COVID-19 vaccine to Ukraine.
"We welcome the breakthrough achieved by the German company BioNTech together with the American company Pfizer in the development of a coronavirus vaccine. This is very encouraging news. I would like to ask for your assistance in taking into account the interests of Ukraine when planning the supply of COVID-19 vaccine," Zelensky said, according to the press service of the Ukrainian President's Office.
Pfizer vaccine
Latest news
Latest newsUkraine’s Battlefield Experience Opens New Opportunities in Asia’s Drone Market
19.Jun.2026
Azerbaijan’s Oil Trap: Why the Economy Is Standing Still
18.Jun.2026
Motorcycle Noise Seen as Obstacle to Air Defense Operations in Crimea
17.Jun.2026
Rising Wages and Euro Integration: Bulgaria Enters a New Economic Era
17.Jun.2026
Armenia After June 7: Pashinyan Remains in Power, Moscow Unhappy
17.Jun.2026
$300 Billion Deal: Iran Poised to Receive the Largest Investment Package in Modern Middle Eastern History
16.Jun.2026
Infrastructure Pressure: Putin Acknowledges the Economic Impact of Ukrainian Attacks
15.Jun.2026
Kyiv and Moscow Trade Blame After Damage Reported at Kyiv Pechersk Lavra
15.Jun.2026
IMF Raises Georgia’s Economic Growth Forecast to 6.5% for 2026
15.Jun.2026
EU Opens the Door to Ukraine and Moldova as First Membership Talks Begin
14.Jun.2026

24 Jun 2026


